let’s talk

中文

|| About

DEGRON THERAPEUTICS

Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective MGD compounds to meet unmet medical needs in all therapeutic areas.

  • Focus

    Molecular glue protein degradation platform to discover novel drugs

  • Unmet Need

    About 80% of disease targets are "undruggable" by existing technologies

  • Our Solution

    Innovative molecular glue degraders to drug the "undruggable" targets and bring a new class of treatment for various diseases

2021

2021

Founded in 2021
Professional and Dedicated

$32M

$32M

Raised from blue chip venture capital investors

20+

20+

Molecular glue discovery platform accelerating a broad pipeline of more than 20 projects

40+

40+

In vitro and in vivo target discovery and validation techniques

INNOVATION
INNOVATION


Dedicate to the research and clinical development of novel molecular glue degraders
INNOVATION=TALENT ADVANTAGE+SCIENCE-DRIVEN

Collaboration Opportunities

Partnership based on the demands

Learn more

01

Global leading drug discovery platform for novel molecular glue degraders

02

Efficient identification and validation of disease-specific targets

03

Targeting undruggable targets that are difficult to drug via traditional approaches; novel targets and first-in-class compounds

04

Available for all therapeutic areas; global and regional out-license

了解更多

NEWS

NEWS

Contact us